IP Library Patent Application 14046995
Patent Application
App. No. 14/046,995

PLASMA PROTEIN CONCENTRATE FOR CELL DELIVERY IN REGENERATIVE APPLICATIONS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/046,995
Abstract

The invention is directed to concentrating autologously-derived plasma, using the concentrated plasma fluid to dilute the patient's cells and applying the combination of concentrated fluid with cells at a site of pathology or mixing the combination of concentrated fluid with cells with a particulate material like a bone void filler prior to placing the mixture at a site of pathology.

Claims (35)

1 . A method of preparing an enriched plasma-derived fluid, the method comprising:

preparing plasma protein concentrate;

preparing regenerative cells; and

combining the plasma protein concentrate with the regenerative cells to form an enriched plasma-derived fluid.

2 . The method of claim 1 , wherein the plasma protein concentrate is prepared by filtration, ultracentrifugation, cold precipitation or lyophilization.

3 . The method of claim 1 , wherein the regenerative cells are derived from bone, bone marrow, adipose, dermis or any combination thereof.

4 . The method of claim 1 , wherein the plasma protein concentrate is derived from peripheral blood or bone marrow aspirate.

5 . A method for improving cell adhesion and retention on a substrate, the method comprising the steps of:

coating plasma protein concentrate on a surface of the substrate;

applying cells or protein on the coated substrate; and

assessing the adhesion and retention of the cells or protein on the coated substrate.

6 . The method of claim 5 , wherein the plasma protein concentrate is prepared by filtration, ultracentrifugation, cold precipitation or lyophilization.

7 . The method of claim 5 , wherein the regenerative cells are derived from bone, bone marrow, adipose, dermis or any combination thereof.

8 . The method of claim 5 , wherein the plasma protein concentrate is derived from peripheral blood or bone marrow aspirate.

9 . A method for improving cell adhesion and retention in a treatment site, the method comprising;

preparing an enriched plasma-derived fluid;

introducing the enriched plasma-derived fluid to a treatment site; and

applying regenerative cells or proteins to the treatment site.

10 . The method of claim 9 , wherein the plasma protein concentrate is prepared by filtration, ultracentrifugation, cold precipitation or lyophilization.

11 . The method of claim 9 , wherein the regenerative cells are derived from bone, bone marrow, adipose, dermis or any combination thereof.

12 . The method of claim 9 , wherein the plasma protein concentrate is derived from peripheral blood or bone marrow aspirate.

13 . A method for improving cell adhesion and retention in a treatment site, the method comprising;

preparing an enriched plasma-derived fluid;

preparing regenerative cells;

mixing the enriched plasma-derived fluid with the regenerative cells; and

introducing the mixture of the enriched plasma-derived fluid and regenerative cells to a treatment site.

14 . The method of claim 13 , wherein the plasma protein concentrate is prepared by filtration, ultracentrifugation, cold precipitation or lyophilization.

15 . The method of claim 13 , wherein the regenerative cells are derived from bone, bone marrow, adipose, dermis or any combination thereof.

16 . The method of claim 13 , wherein the plasma protein concentrate is derived from peripheral blood or bone marrow aspirate.

17 . A method for improving cell adhesion and retention in a treatment site, the method comprising;

preparing a particulate material;

preparing regenerative cells;

mixing the particulate material with the regenerative cells; and

introducing the mixture of the enriched plasma-derived fluid and regenerative cells to a treatment site.

18 . The method of claim 17 wherein the particulate material is bone void filler.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Apr 10, 2019
From: AMERICAN BANK
To: SPINESMITH HOLIDNGS, LLC
Reel/Frame 048853/0105 →
RELEASE OF SECURITY INTEREST Recorded Apr 10, 2019
From: SILICON VALLEY BANK
To: SPINESMITH HOLDINGS, LLC
Reel/Frame 048853/0183 →
SECURITY INTEREST Recorded Dec 14, 2017
From: SPINESMITH HOLDINGS, LLC
To: AMERICAN BANK, N.A.
Reel/Frame 044882/0096 →
SECURITY INTEREST Recorded Mar 22, 2017
From: SPINESMITH HOLDINGS, LLC
To: BLUEARC MEZZANINE PARTNERS I, L.P.
Reel/Frame 042071/0370 →
SECURITY INTEREST Recorded Feb 18, 2015
From: SPINESMITH HOLDINGS, LLC
To: SILICON VALLEY BANK
Reel/Frame 035014/0066 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2013
From: MURPHY, MATTHEW; SAND, THEODORE
To: SPINESMITH PARTNERS, L.P.
Reel/Frame 031374/0959 →